Effectiveness and safety of gemcitabine plus nab-paclitaxel in elderly patients with advanced pancreatic cancer: a single-center retrospective cohort study.
Elderly patient
Gemcitabine plus nab-paclitaxel
Overall survival
Pancreatic cancer
S-1
Journal
Investigational new drugs
ISSN: 1573-0646
Titre abrégé: Invest New Drugs
Pays: United States
ID NLM: 8309330
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
28
12
2021
accepted:
31
01
2022
pubmed:
29
7
2022
medline:
25
8
2022
entrez:
28
7
2022
Statut:
ppublish
Résumé
This study aimed to evaluate the effectiveness and safety of gemcitabine (GEM) plus nab-paclitaxel (GnP) in patients aged ≥ 75 years with advanced pancreatic cancer and compare it with monotherapy (GEM or S-1). We retrospectively reviewed the data of consecutive patients with advanced pancreatic cancer aged ≥ 75 years who received either GnP or monotherapy (GEM or S-1) between January 2014 and May 2020. The primary efficacy outcome was overall survival (OS). A total of 96 patients were included in this study; 51 were treated with GnP and 45 with monotherapy (31 with GEM and 14 with S-1). The median OS and progression-free survival were 10.8 and 6.7 months in the GnP group and 10.7 and 4.3 months in the monotherapy group, respectively. The treatment effect on OS was consistently favorable in the GnP group across most subgroups, particularly in patients with locally advanced cancer, modified Glasgow prognostic score of 0 or 1, and neutrophil/lymphocyte ratio < 3.1. The disease control rates were 76% and 48% in the GnP and monotherapy groups, respectively, and grade 3 or 4 neutropenia occurred in 23 (45%) and 11 (24%) patients of the GnP and monotherapy groups, respectively. This study demonstrated that GnP was not superior to monotherapy with regard to OS. However, multivariate analysis showed that GnP treatment positively affected the OS and could be considered as a treatment option, even for elderly patients.
Identifiants
pubmed: 35900709
doi: 10.1007/s10637-022-01221-x
pii: 10.1007/s10637-022-01221-x
doi:
Substances chimiques
130-nm albumin-bound paclitaxel
0
Albumins
0
Deoxycytidine
0W860991D6
Paclitaxel
P88XT4IS4D
Gemcitabine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1106-1116Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Kuroda T, Kumagi T, Yokota T, Seike H, Nishiyama M, Imai Y, Inada N, Shibata N, Imamine S, Okada S, Koizumi M, Yamanishi H, Azemoto N, Miyaike J, Tanaka Y, Tatsukawa H, Utsunomiya H, Ohno Y, Miyake T, Hirooka M, Furukawa S, Abe M, Ikeda Y, Matsuura B, Hiasa Y, Onji M, EPOCH Study Group (2013) Improvement of long-term outcomes in pancreatic cancer and its associated factors within the gemcitabine era: a collaborative retrospective multicenter clinical review of 1,082 patients. BMC Gastroenterol 13:134. https://doi.org/10.1186/1471-230X-13-134
doi: 10.1186/1471-230X-13-134
Heinemann V (2002) Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. Semin Oncol 29(Supplement 20):9–16. https://doi.org/10.1053/sonc.2002.37372
doi: 10.1053/sonc.2002.37372
pubmed: 12577228
Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267–277. https://doi.org/10.1001/jama.297.3.267
doi: 10.1001/jama.297.3.267
pubmed: 17227978
Van den Broeck A, Sergeant G, Ectors N, Van Steenbergen W, Aerts R, Topal B (2009) Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol 35:600–604. https://doi.org/10.1016/j.ejso.2008.12.006
doi: 10.1016/j.ejso.2008.12.006
pubmed: 19131205
Ministry of Health, Labour and Welfare (2018) [Center for Cancer Control and Information Services, National Cancer Center, Japan web site]. Vital Stat Jpn. https://ganjoho.jp/reg_stat/statistics/dl/index.html#mortality . Accessed 26 Nov 2020
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M, Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825. https://doi.org/10.1056/NEJMoa1011923
doi: 10.1056/NEJMoa1011923
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703. https://doi.org/10.1056/NEJMoa1304369
doi: 10.1056/NEJMoa1304369
Yamagishi Y, Higuchi H, Izumiya M, Sakai G, Iizuka H, Nakamura S, Adachi M, Hozawa S, Takaishi H, Hibi T (2010) Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma. J Gastroenterol 45:1146–1154. https://doi.org/10.1007/s00535-010-0258-9
doi: 10.1007/s00535-010-0258-9
pubmed: 20549255
Katakura Y, Nakahara K, Kobayashi M, Adachi S, Izawa N, Noguchi Y, Nakatsu S, Sato Y, Takagi R, Itoh F (2010) Gemcitabine therapy for unresectable pancreatic cancer in elderly patients. Nihon Shokakibyo Gakkai Zasshi 107:396–406 (in Japanese)
pubmed: 20203443
Imaoka H, Kou T, Tanaka M, Egawa S, Mizuno N, Hijioka S, Hara K, Yazumi S, Shimizu Y, Yamao K (2016) Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: subgroup analysis of a randomised phase III trial, GEST study. Eur J Cancer 54:96–103. https://doi.org/10.1016/j.ejca.2015.11.002
doi: 10.1016/j.ejca.2015.11.002
pubmed: 26741729
Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, Chen JS, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Okusaka T, Tanaka M (2013) Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 31:1640–1648. https://doi.org/10.1200/JCO.2012.43.3680
doi: 10.1200/JCO.2012.43.3680
pubmed: 23547081
Jin J, Teng C, Li T (2018) Combination therapy versus gemcitabine monotherapy in the treatment of elderly pancreatic cancer: a meta-analysis of randomized controlled trials. Drug Des Dev Ther 12:475–480. https://doi.org/10.2147/DDDT.S156766
doi: 10.2147/DDDT.S156766
Stein SM, James ES, Deng Y, Cong X, Kortmansky JS, Li J, Staugaard C, Indukala D, Boustani AM, Patel V, Cha CH, Salem RR, Chang B, Hochster HS, Lacy J (2016) Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer 114:737–743. https://doi.org/10.1038/bjc.2016.45
doi: 10.1038/bjc.2016.45
pubmed: 27022826
Blomstrand H, Scheibling U, Bratthäll C, Green H, Elander NO (2019) Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer. BMC Cancer 19:40. https://doi.org/10.1186/s12885-018-5244-2
doi: 10.1186/s12885-018-5244-2
pubmed: 30621618
pmcid: 6325739
Sørensen JB, Klee M, Palshof T, Hansen HH (1993) Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 67:773–775. https://doi.org/10.1038/bjc.1993.140
doi: 10.1038/bjc.1993.140
pubmed: 8471434
pmcid: 1968363
Krishnan S, Rana V, Janjan NA, Abbruzzese JL, Gould MS, Das P, Delclos ME, Palla S, Guha S, Varadhachary G, Evans DB, Wolff RA, Crane CH (2006) Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer 107:2589–2596. https://doi.org/10.1002/cncr.22328
doi: 10.1002/cncr.22328
pubmed: 17083124
Weber A, Kehl V, Mittermeyer T, Herberich E, Röthling N, Schmid RM, Prinz C (2010) Prognostic factors for survival in patients with unresectable pancreatic cancer. Pancreas 39:1247–1253. https://doi.org/10.1097/MPA.0b013e3181e21b1b
doi: 10.1097/MPA.0b013e3181e21b1b
pubmed: 20683218
Tas F, Sen F, Odabas H, Kılıc L, Keskın S, Yıldız I (2013) Performance status of patients is the major prognostic factor at all stages of pancreatic cancer. Int J Clin Oncol 18:839–846. https://doi.org/10.1007/s10147-012-0474-9
doi: 10.1007/s10147-012-0474-9
pubmed: 22996141
Hwang I, Kang J, Ip HNN, Jeong JH, Kim KP, Chang HM, Yoo C, Ryoo BY (2019) Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores. Investig New Drugs 37:584–590. https://doi.org/10.1007/s10637-018-0681-y
doi: 10.1007/s10637-018-0681-y
Shimoda M, Katoh M, Kita J, Sawada T, Kubota K (2010) The Glasgow prognostic score is a good predictor of treatment outcome in patients with unresectable pancreatic cancer. Chemotherapy 56:501–506. https://doi.org/10.1159/000321014
doi: 10.1159/000321014
pubmed: 21099223